[{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"9e22f735-9f0d-4c3a-92fb-91f43ae1a4bd","acronym":"TROPION-LUNG01","url":"https://clinicaltrials.gov/study/NCT04656652","created_at":"2021-01-19T20:41:43.327Z","updated_at":"2025-02-25T14:59:32.426Z","phase":"Phase 3","brief_title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","source_id_and_acronym":"NCT04656652 - TROPION-LUNG01","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 06/21/2025","study_completion_date":" 06/21/2025","last_update_posted":"2025-02-13"},{"id":"7204e2a6-dc66-4d87-87cb-75b6b508cd0a","acronym":"KisMET-01","url":"https://clinicaltrials.gov/study/NCT05652868","created_at":"2022-12-15T14:58:22.414Z","updated_at":"2025-02-25T15:20:09.822Z","phase":"Phase 1","brief_title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05652868 - KisMET-01","lead_sponsor":"Mythic Therapeutics","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYTX-011"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 03/23/2023","start_date":" 03/23/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-12"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"dab562b9-279d-4fe8-b2fc-7ee0c721ed02","acronym":"KUNPENG-2","url":"https://clinicaltrials.gov/study/NCT05989542","created_at":"2023-08-14T14:10:14.391Z","updated_at":"2025-02-25T16:40:06.600Z","phase":"Phase 3","brief_title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","source_id_and_acronym":"NCT05989542 - KUNPENG-2","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" EGFR • KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement","tags":["EGFR • KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"af8a3284-49b9-490f-b1b7-982ed6e7b88b","acronym":"POTENT","url":"https://clinicaltrials.gov/study/NCT05782361","created_at":"2023-03-23T14:03:00.081Z","updated_at":"2025-02-25T16:18:40.803Z","phase":"Phase 1","brief_title":"POTENT - Tepotinib in Combination with Pembrolizumab in NSCLC","source_id_and_acronym":"NCT05782361 - POTENT","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-10-01"},{"id":"a6e18105-9457-47d7-93da-0d2d96852d1c","acronym":"HCRN LUN21-497","url":"https://clinicaltrials.gov/study/NCT05617313","created_at":"2022-11-15T15:57:34.931Z","updated_at":"2025-02-25T16:18:18.717Z","phase":"Phase 2","brief_title":"Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05617313 - HCRN LUN21-497","lead_sponsor":"Jeffrey Clarke","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" KRAS G12C • MET exon 14 mutation • KRAS G12","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • MET exon 14 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • GT103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 02/17/2023","start_date":" 02/17/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-07-19"},{"id":"fe03cda1-1670-4c2f-aa16-3697bbbeabf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04575025","created_at":"2021-01-27T19:00:57.694Z","updated_at":"2024-07-02T16:34:25.927Z","phase":"","brief_title":"Special Drug Use-results Surveillance of Tabrecta Tablets","source_id_and_acronym":"NCT04575025","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 11/02/2020","start_date":" 11/02/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-06-14"},{"id":"242a00a6-2e7d-4b18-8a4a-57905c77b105","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05364645","created_at":"2022-05-06T18:55:15.353Z","updated_at":"2024-07-02T16:34:27.438Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05364645 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/27/2023","primary_completion_date":" 06/27/2023","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-11"},{"id":"ba697a0c-0213-4400-8a69-554239875d35","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04268550","created_at":"2021-01-18T14:26:41.644Z","updated_at":"2024-07-02T16:34:59.356Z","phase":"Phase 2","brief_title":"Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04268550 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-06-04"},{"id":"f52ea7ba-bfbd-4917-b198-17afffc30288","acronym":"","url":"https://clinicaltrials.gov/study/NCT05553834","created_at":"2022-09-23T17:07:20.162Z","updated_at":"2024-07-02T16:35:01.068Z","phase":"Phase 2","brief_title":"PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","source_id_and_acronym":"NCT05553834","lead_sponsor":"Duke University","biomarkers":" EGFR • BRAF • MET • ROS1 • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Praluent (alirocumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2024-05-24"},{"id":"4d7b9d47-ea39-4190-9ede-c3f2ba2819fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05541822","created_at":"2022-09-15T14:59:05.101Z","updated_at":"2024-07-02T16:35:02.112Z","phase":"Phase 2","brief_title":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","source_id_and_acronym":"NCT05541822","lead_sponsor":"Abion Inc","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vabametkib (ABN401)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-22"},{"id":"d61ddbc3-bb32-4dda-8c4c-406b6f74dc87","acronym":"HARMONIC","url":"https://clinicaltrials.gov/study/NCT05456256","created_at":"2022-07-13T12:56:31.097Z","updated_at":"2024-07-02T16:35:03.235Z","phase":"Phase 2","brief_title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT05456256 - HARMONIC","lead_sponsor":"Lantern Pharma Inc.","biomarkers":" EGFR • ALK • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • ALK • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Pemfexy (pemetrexed) • Tavocept (dimesna)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-05-16"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"a3747950-095a-48c6-aa37-bde9bcafea6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083857","created_at":"2023-10-16T16:13:46.888Z","updated_at":"2024-07-02T16:35:06.404Z","phase":"Phase 1/2","brief_title":"PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06083857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-05-02"},{"id":"677edd33-9a1c-430c-98a8-3977cf1e241f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05110196","created_at":"2021-11-05T12:53:26.883Z","updated_at":"2024-07-02T16:35:07.074Z","phase":"Phase 4","brief_title":"Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.","source_id_and_acronym":"NCT05110196","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK • MET","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation","tags":["EGFR • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/03/2022","start_date":" 09/03/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-04-29"},{"id":"12564864-7d8c-467b-ba26-fc5db317bd65","acronym":"","url":"https://clinicaltrials.gov/study/NCT05120960","created_at":"2021-11-16T13:54:01.498Z","updated_at":"2024-07-02T16:35:09.062Z","phase":"Phase 1","brief_title":"A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors","source_id_and_acronym":"NCT05120960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tepmetko (tepotinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 04/12/2024","primary_completion_date":" 04/12/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-17"},{"id":"a4db82ac-25ea-4169-8bb8-cb613afd0358","acronym":"ATATcH","url":"https://clinicaltrials.gov/study/NCT05358548","created_at":"2022-05-03T14:53:59.407Z","updated_at":"2024-07-02T16:35:10.415Z","phase":"Phase 2","brief_title":"ATATcH Alternating Treatment Plans for Advanced Cancer","source_id_and_acronym":"NCT05358548 - ATATcH","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-10"},{"id":"8c27375e-dbbf-4085-930d-9f071f33e371","acronym":"TROPION-Lung05","url":"https://clinicaltrials.gov/study/NCT04484142","created_at":"2021-01-18T21:31:48.583Z","updated_at":"2025-02-25T14:59:16.191Z","phase":"Phase 2","brief_title":"Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)","source_id_and_acronym":"NCT04484142 - TROPION-Lung05","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MET exon 14 mutation","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 03/30/2021","start_date":" 03/30/2021","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"12fc2fab-0693-4b13-abf9-14c2d2d11df7","acronym":"ELEVATELung\u0026UC","url":"https://clinicaltrials.gov/study/NCT04827576","created_at":"2021-04-01T15:52:23.578Z","updated_at":"2024-07-02T16:35:13.353Z","phase":"Phase 2","brief_title":"Study of Magrolimab in Patients With Solid Tumors","source_id_and_acronym":"NCT04827576 - ELEVATELung\u0026UC","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • ALK • ROS1 • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-21"},{"id":"40df6160-751e-485f-9648-832a744ed37a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077099","created_at":"2021-01-18T19:58:00.182Z","updated_at":"2024-07-02T16:35:16.114Z","phase":"Phase 1/2","brief_title":"REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04077099","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e davutamig (REGN5093)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 10/20/2024","study_completion_date":" 10/20/2024","last_update_posted":"2024-03-06"}]